Metastatic Hepatocellular Carcinoma (HCC) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) – Drugs In Development, 2023’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3D Medicines IncAbbisko Therapeutics Co Ltd
AbbVie Inc
Akeso Inc
Alphamab Oncology
Amgen Inc
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Syngentech Co Ltd
Bio-Thera Solutions Ltd
Biosplice Therapeutics Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Chengdu Huajian Future Science And Technology Co Ltd
Chengdu New Radiomedicine Technology Co Ltd
Chugai Pharmaceutical Co Ltd
Codiak BioSciences Inc
Coherus BioSciences Inc
CStone Pharmaceuticals Co Ltd
Cyclacel Pharmaceuticals Inc
Dracen Pharmaceuticals Inc
Dyadic International Inc
DynamiCure Biotechnology LLC
Eisai Co Ltd
Eli Lilly and Co
EpimAb Biotherapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fujian Cancer Hospital
Genentech USA Inc
Geneos Therapeutics Inc
GenFleet Therapeutics (Shanghai) Inc
Genoscience Pharma
Guangzhou Virotech Pharmaceutical Co Ltd
Hangzhou Neoantigen Therapeutics Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Hope Biosciences LLC
Huabo Biopharm (Shanghai) Co Ltd
Huahui Health Ltd
ImmuneOncia Therapeutics Inc
ImmuneSensor Therapeutics Inc
Incyte Corp
Innovent Biologics Inc
Intensity Therapeutics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kintor Pharmaceutical Ltd
Lyvgen Biopharma Ltd
Minghui Pharmaceutical (Shanghai) Co Ltd
Mirati Therapeutics Inc
Molecular Templates Inc
Multitude therapeutics Inc
NeoTX Therapeutics Ltd
NewG Lab Pharma Co Ltd
Oasis Pharmaceuticals LLC
OncoC4 Inc
Otsuka Pharmaceutical Co Ltd
Qurient Co Ltd
RemeGen Co Ltd
Salubris Biotherapeutics Inc
Sanofi
SciClone Pharmaceuticals Holdings Ltd
Shanghai Henlius Biotech Inc
Shenogen Pharma Group Ltd
Simcere Pharmaceutical Group Ltd
SOTIO Biotech AS
Sun Yat-sen University
TCM Biotech International Corp
Tempest Therapeutics Inc
Tiziana Life Sciences Plc
Tvardi Therapeutics Inc
Virogin Biotech Ltd
Wuhan YZY Biopharma Co Ltd
Xencor Inc
Xuzhou Medical University
Zai Lab (Shanghai) Co Ltd